Researchers at Aarhus University in Denmark detected the GLP-1 hormone targeted by drugs such as Wegovy in the joint fluid of arthritis patients, suggesting weight-loss medications might influence inflammation locally rather than only through metabolic effects.
The study published in The Lancet Rheumatology analyzed paired blood and synovial fluid samples from people with rheumatoid arthritis and spondyloarthritis. GLP-1 concentrations in joints closely tracked blood levels, indicating the hormone reaches joint tissue from circulation.
Associate Professor Tue Wenzel Kragstrup said natural GLP-1 amounts in joints are tiny, but pharmacological doses used for diabetes and obesity treatment are far higher and could potentially act on inflammatory pathways. Patients on these drugs have anecdotally reported reduced joint pain, though causation was not established.
Scientists stressed the findings do not prove GLP-1 medications treat arthritis and called for clinical trials before any therapeutic claims. The work opens a research path distinct from weight reduction alone as a mechanism for symptom improvement in inflammatory joint disease.
Researchers analyzed samples from the InART biobank at Aarhus University Hospital involving rheumatoid arthritis and spondyloarthritis patients alongside healthy volunteers. PhD student Mads Brüner found joint fluid GLP-1 levels closely mirrored bloodstream concentrations, suggesting passive transfer rather than local production. Kragstrup’s team planned collaborations with Steno Diabetes Center to study patients receiving GLP-1 therapy or bariatric surgery.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/